Securities code: Shenzhen Hepalink Pharmaceutical Group Co.Ltd(002399) securities abbreviation: Shenzhen Hepalink Pharmaceutical Group Co.Ltd(002399) Announcement No.: 2022020 Shenzhen Hepalink Pharmaceutical Group Co.Ltd(002399)
First quarter report of 2022
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions. ‡ important content tips: 1 The board of directors, the board of supervisors, directors, supervisors and senior managers guarantee that the quarterly report is true, accurate and complete without false records, misleading statements or major omissions, and bear individual and joint legal liabilities. 2. The person in charge of the company, the person in charge of accounting and the person in charge of the accounting organization (Accounting Supervisor) declare that they guarantee the authenticity, accuracy and completeness of the financial information in the quarterly report. 3. Whether the first quarter report has been audited □ yes √ No 1. Main financial data (I) whether the company needs to retroactively adjust or restate the accounting data of previous years □ yes √ no
Increase or decrease in the reporting period compared with the same period of the previous year
Operating income (yuan): 191032374574126787679645 50.67%
Net profit attributable to shareholders of listed company (yuan): 2349433716514348326673 63.74%
Net profit attributable to shareholders of listed company after deducting non recurring loss 1658462283511451199979 44.83% (yuan)
Net cash flow from operating activities (yuan) -13788272841980668716 -100.33%
Basic earnings per share (yuan / share) 0.1601 0.097863.70%
Diluted earnings per share (yuan / share) 0.1601 0.097863.70%
Weighted average return on net assets 2.04%, 1.23%, 0.81%
Increase or decrease at the end of the reporting period compared with the end of the previous year
Total assets (yuan) 20130476736541910817526678 5.35%
Owner’s equity attributable to shareholders of listed company (yuan): 1164123445531141135445588 2.01%
（2） □ amount of non recurring items and inapplicability
Unit: Yuan
Description of the amount of the project in the current reporting period
Gains and losses on disposal of non current assets (including the write off part of the provision for asset impairment) 5440151
Government subsidies included in current profits and losses (closely related to the company’s normal business, consistent with
Government subsidy 1088683142 in accordance with national policies and regulations and in accordance with certain standard quota or quota
(excluding AIDS)
Including financial products, derivative financial assets, convertible bonds, equity investment and fund investment, in addition to the effective hedging business related to the company’s normal business, the profit and loss from changes in fair value arising from holding trading assets, the profit and loss from changes in fair value arising from common financial assets and trading financial liabilities, And 6639417049, totaling 6075009837 yuan, as well as the disposal of trading financial assets, trading financial liabilities and available for sale financial assets, financial products obtained during the holding period, investment income, equity investment, fund investment The dividends, transfer gains, interest and other investment income of debt investment totaled 564407212 yuan
Other non operating income and expenditure other than the above -83777805
Less: income tax impact 711611048
Influence amount of minority shareholders’ equity (after tax) 28437159
Total 6909714330–
Details of other profit and loss items that meet the definition of non recurring profit and loss: □ applicable √ not applicable. The company does not have details of other profit and loss items that meet the definition of non recurring profit and loss.
Description of defining the non recurring profit and loss items listed in the explanatory announcement on information disclosure of companies offering securities to the public No. 1 – non recurring profit and loss as recurring profit and loss items □ applicable √ not applicable the company does not define the non recurring profit and loss items listed in the explanatory announcement on Information Disclosure of companies offering securities to the public No. 1 – non recurring profit and loss as recurring profit and loss items. （3） Changes and reasons of main accounting data and financial indicators √ applicable □ not applicable 1. Balance sheet items
Reasons for year-on-year increase and decrease of the project at the end of the reporting period and the end of the previous year
Accounts payable 5378851016338578664507 39.43% was mainly due to the increase in the purchase amount of raw materials in the reporting period
2. Income statement items
Reasons for year-on-year increase and decrease of the project in the reporting period
The operating revenue of 191032374574 and 126787679645 was mainly due to the increase in the revenue of preparation business, heparin sodium and low molecular weight 50.67% heparin sodium API business in the reporting period
The operating cost was 13311589556584990113530 56.63%, mainly due to the growth of sales volume in the reporting period
Sales expenses 120294534928866759346 35.67% were mainly due to the increase of marketing expenses in the reporting period
Credit impairment loss was -966324163 -234906254 and 311.37%, mainly due to the increase of expected credit loss at the end of the reporting period
Other income 1088683142480627012 126.51% was mainly due to the year-on-year increase in government subsidies received in the reporting period
Investment income -30599687003239393046 is mainly due to the increase of investment loss recognized by -194.46% equity share of long-term equity investment accounted by equity method in the reporting period
The income from changes in fair value was 6087821644870064103 599.70%, mainly due to the year-on-year increase in the income from changes in fair value of financial assets in the reporting period
Operating profit 2834901353218225624568 55.54% was mainly due to the increase of gross profit in the reporting period
Non operating expenditure was 85836703, 18870899 and 354.86%, mainly due to the increase of external donation expenditure in the reporting period
The total profit is 2826490849218208607408 55.23%. See the analysis of the reasons for the change of operating profit
The net profit is 2352392088314267790444 64.87%. See the analysis of the reasons for the change of operating profit
The net after tax amount of other comprehensive income was -453287812798301163, which was mainly due to the combined impact of the fluctuation of international exchange rate and the change of fair value of other equity investments of – 156.78%
3. Cash flow statement items
Reasons for year-on-year increase and decrease of the project in the reporting period
The cash flow from operating activities is mainly due to the year-on-year increase of -13788272841980668716 – 100.33% of the net cash paid for purchasing goods and receiving labor services in the reporting period, which is greater than the year-on-year increase of cash received from selling goods and providing labor services
The cash flow generated from investment activities is mainly cash flow transferred into time deposits by the company during the reporting period
